Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat
Vivoryon Therapeutics N.V. (VVY) has strengthened its intellectual property portfolio with a new U.S. composition of matter patent for its lead drug varoglutamstat. The patent (US 12,312,335), granted after an accelerated examination, covers the active polymorph of varoglutamstat's salt form and provides exclusivity through 2044, with potential extension to 2049 under the Hatch-Waxman Act.
The company has also filed additional patents for medical use and dosing regimens in kidney disease, both as monotherapy and in combination with SGLT-2 inhibitors. Vivoryon's patent portfolio includes over 20 patent families and 400+ patent applications and issued patents covering major markets, with a focus on QPCT/L inhibitors for kidney diseases, inflammatory diseases, oncology, and fibrotic diseases.
Vivoryon Therapeutics N.V. (VVY) ha rafforzato il suo portafoglio di proprietà intellettuale con un nuovo brevetto statunitense sulla composizione del suo farmaco principale, varoglutamstat. Il brevetto (US 12,312,335), concesso dopo un esame accelerato, copre il polimorfo attivo della forma salina di varoglutamstat e garantisce l'esclusività fino al 2044, con possibile estensione fino al 2049 secondo l'Hatch-Waxman Act.
L'azienda ha inoltre depositato ulteriori brevetti per l'uso medico e i regimi posologici nelle malattie renali, sia come monoterapia sia in combinazione con inibitori SGLT-2. Il portafoglio brevetti di Vivoryon comprende oltre 20 famiglie di brevetti e più di 400 domande e brevetti concessi che coprono i principali mercati, con un focus sugli inibitori QPCT/L per malattie renali, infiammatorie, oncologiche e fibrotiche.
Vivoryon Therapeutics N.V. (VVY) ha fortalecido su cartera de propiedad intelectual con una nueva patente estadounidense sobre la composición de su medicamento principal, varoglutamstat. La patente (US 12,312,335), otorgada tras un examen acelerado, cubre el polimorfo activo de la forma salina de varoglutamstat y ofrece exclusividad hasta 2044, con posible extensión hasta 2049 bajo la Ley Hatch-Waxman.
La compañía también ha presentado patentes adicionales para el uso médico y regímenes de dosificación en enfermedades renales, tanto en monoterapia como en combinación con inhibidores SGLT-2. La cartera de patentes de Vivoryon incluye más de 20 familias de patentes y más de 400 solicitudes y patentes concedidas que cubren los principales mercados, con un enfoque en inhibidores QPCT/L para enfermedades renales, inflamatorias, oncológicas y fibróticas.
Vivoryon Therapeutics N.V. (VVY)는 주력 약물인 바로글루탐스타트(varoglutamstat)의 새로운 미국 조성물 특허를 통해 지적 재산권 포트폴리오를 강화했습니다. 이 특허(US 12,312,335)는 가속 심사 후 부여되었으며, 바로글루탐스타트 염 형태의 활성 폴리모프를 포함하며 2044년까지 독점권을 제공하고, Hatch-Waxman 법에 따라 2049년까지 연장 가능성이 있습니다.
회사는 신장 질환에서 단독 요법 및 SGLT-2 억제제와의 병용 요법에 대한 의료용도 및 투여 요법에 관한 추가 특허도 출원했습니다. Vivoryon의 특허 포트폴리오는 주요 시장을 대상으로 하는 20개 이상의 특허 군과 400건 이상의 특허 출원 및 등록 특허를 포함하며, 신장 질환, 염증성 질환, 종양학, 섬유증 질환을 위한 QPCT/L 억제제에 중점을 두고 있습니다.
Vivoryon Therapeutics N.V. (VVY) a renforcé son portefeuille de propriété intellectuelle avec un nouveau brevet américain portant sur la composition de son médicament principal, le varoglutamstat. Le brevet (US 12,312,335), délivré après un examen accéléré, couvre le polymorphe actif de la forme saline du varoglutamstat et offre une exclusivité jusqu'en 2044, avec une extension possible jusqu'en 2049 selon la loi Hatch-Waxman.
L'entreprise a également déposé des brevets supplémentaires pour l'utilisation médicale et les schémas posologiques dans les maladies rénales, en monothérapie ou en association avec des inhibiteurs SGLT-2. Le portefeuille de brevets de Vivoryon comprend plus de 20 familles de brevets et plus de 400 demandes et brevets délivrés couvrant les principaux marchés, avec un focus sur les inhibiteurs QPCT/L pour les maladies rénales, inflammatoires, oncologiques et fibrosantes.
Vivoryon Therapeutics N.V. (VVY) hat sein geistiges Eigentumsportfolio mit einem neuen US-Patentschutz für die Zusammensetzung seines führenden Medikaments Varoglutamstat erweitert. Das Patent (US 12.312.335), das nach einer beschleunigten Prüfung erteilt wurde, umfasst den aktiven Polymorph der Salzform von Varoglutamstat und bietet Exklusivität bis 2044, mit möglicher Verlängerung bis 2049 gemäß dem Hatch-Waxman-Gesetz.
Das Unternehmen hat außerdem weitere Patente für die medizinische Anwendung und Dosierungsschemata bei Nierenerkrankungen angemeldet, sowohl als Monotherapie als auch in Kombination mit SGLT-2-Inhibitoren. Das Patentportfolio von Vivoryon umfasst über 20 Patentfamilien und mehr als 400 Patentanmeldungen und erteilte Patente für wichtige Märkte, mit Schwerpunkt auf QPCT/L-Inhibitoren für Nierenerkrankungen, Entzündungskrankheiten, Onkologie und fibrotische Erkrankungen.
- New U.S. patent provides long exclusivity period until 2044, with potential extension to 2049
- Patent granted through accelerated examination process, indicating strong IP position
- Extensive IP portfolio with over 20 patent families and 400+ patent applications/issued patents
- Preclinical data shows synergistic effects when combined with SGLT-2 inhibitors
- None.
Insights
Vivoryon's new US patent for varoglutamstat significantly extends exclusivity through 2044, strengthening commercial potential for kidney disease applications.
The newly granted US patent (12,312,335) represents a significant intellectual property milestone for Vivoryon Therapeutics. This composition of matter patent specifically covers the active polymorph of the salt form used in varoglutamstat's drug product, providing exclusivity through 2044, with potential extension to 2049 under the Hatch-Waxman Act.
What makes this particularly notable is the accelerated examination process through which this patent was granted, indicating both the strength of the company's patent application and potentially the novelty of the composition. For a pharmaceutical company, securing composition of matter patents is the gold standard of protection, as they're typically more defensible than method-of-use patents.
The company is also pursuing additional patent protections covering medical use and dosing regimens for varoglutamstat in kidney disease, both as monotherapy and in combination with SGLT-2 inhibitors. This multi-layered patent strategy creates a protective moat around their intellectual property, covering not just the compound itself but its applications and delivery methods.
Vivoryon's broader patent portfolio contains over 20 patent families with more than 400 patent applications and issued patents spanning major markets. The company appears to be strategically shifting focus toward kidney diseases, as evidenced by their recent patent filings. The preclinical data showing synergistic effects when combining varoglutamstat with SGLT-2 inhibitors suggests promising therapeutic potential that this patent protection will help them capitalize on commercially.
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat
- Newly granted U.S. patent expected to provide exclusivity through 2044 with subsequent opportunity for patent term extension
- New U.S. patent granted after accelerated examination process covers the active polymorph of varoglutamstat, Vivoryon’s lead drug in development
- Additional patents for medical use and dosing regimens under examination for varoglutamstat and related structures in kidney disease as monotherapy and in combination with SGLT-2 inhibitors
Halle (Saale) / Munich, Germany, May 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent covering the Company’s lead drug in development, varoglutamstat. The new patent was granted after an accelerated examination process.
“Vivoryon pursues a diligent and comprehensive strategy to continuously strengthen the intellectual property protecting our key assets on multiple levels. This successful patent application demonstrates our strong commitment to protecting the innovation of our lead asset varoglutamstat and is an important milestone for Vivoryon. The fact that it has been granted several months ahead of the anticipated timing is a testament to the outstanding work of our team,” said Frank Weber, MD, CEO of Vivoryon. “We expect that this long patent runway will support our efforts to maximize the full therapeutic potential of varoglutamstat, which we plan to develop in kidney disease.”
The newly granted composition of matter US patent (US 12,312,335) covers the only polymorph of the salt form used in the drug product of Vivoryon’s unique QPCT/L inhibitor varoglutamstat. The patent has a scheduled runtime through 2044, with the subsequent opportunity for a patent term extension of up to five years to 2049 under the Hatch-Waxman Act.
In addition, the Company has filed a number of different patents in its focus area of kidney disease over the past months. These relate to varoglutamstat and related structures, covering medical use, and dosing regimens, both as monotherapy and in combination with standard of care, namely SGLT-2 inhibitors. Adding an additional layer of protection, the patent applications cover the free base and all salt forms of varoglutamstat and are currently under examination.
Vivoryon has a strong patent portfolio for QPTC/L inhibition and continues to evolve its IP strategy based on scientific evidence, striving to bolster its IP portfolio on multiple levels. Patent applications and granted patents span composition of matter, medical use as well as indications and dosing regimens. Recent additions to the portfolio relate to the Company’s primary field of focus, diseases of the kidney and include patents for the combination of QPCT/L inhibitors with standard of care, SGLT-2 inhibitors. These patents were filed based on the outstanding effect observed in preclinical research, where data revealed synergistic effect of the combination treatment with varoglutamstat and an SGLT-2 inhibitor with both once and twice daily treatment.
The Company has a strong patent portfolio relating to QPCT/L inhibitors in a broad range of diseases with high medical need, including kidney diseases, inflammatory diseases, oncology, genetic and fibrotic diseases. The portfolio is comprised of over 20 patent families and over 400 patent applications and issued patents covering all major markets, with composition of matter patents on QPCT/L inhibitors representing the clear majority and with recent patent applications reflecting Vivoryon’s focus on kidney diseases.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer’s disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu
Attachment
FAQ
What is the expiration date of VVY's new varoglutamstat patent?
What does Vivoryon's new patent cover for varoglutamstat?
How many patents does Vivoryon Therapeutics currently hold?
What therapeutic areas are covered by Vivoryon's patent portfolio?
What additional patents is VVY pursuing for varoglutamstat?
